These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32041222)

  • 1. Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-G
    Zimmermann K; Kuehle J; Dragon AC; Galla M; Kloth C; Rudek LS; Sandalcioglu IE; Neyazi B; Moritz T; Meyer J; Rossig C; Altvater B; Eiz-Vesper B; Morgan MA; Abken H; Schambach A
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32041222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD
    Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R
    Front Immunol; 2022; 13():839783. PubMed ID: 35401506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
    Rudek LS; Zimmermann K; Galla M; Meyer J; Kuehle J; Stamopoulou A; Brand D; Sandalcioglu IE; Neyazi B; Moritz T; Rossig C; Altvater B; Falk CS; Abken H; Morgan MA; Schambach A
    Front Immunol; 2021; 12():751138. PubMed ID: 34804035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
    Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
    Clin Cancer Res; 2024 Aug; 30(16):3564-3577. PubMed ID: 38593230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
    Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor.
    Uchibori R; Teruya T; Ido H; Ohmine K; Sehara Y; Urabe M; Mizukami H; Mineno J; Ozawa K
    Mol Ther Oncolytics; 2019 Mar; 12():16-25. PubMed ID: 30662937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
    Hoseini SS; Dobrenkov K; Pankov D; Xu XL; Cheung NK
    Oncoimmunology; 2017; 6(6):e1320625. PubMed ID: 28680755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.
    Smole A; Benton A; Poussin MA; Eiva MA; Mezzanotte C; Camisa B; Greco B; Sharma P; Minutolo NG; Gray F; Bear AS; Baroja ML; Cummins C; Xu C; Sanvito F; Goldgewicht AL; Blanchard T; Rodriguez-Garcia A; Klichinsky M; Bonini C; June CH; Posey AD; Linette GP; Carreno BM; Casucci M; Powell DJ
    Cancer Cell; 2022 Dec; 40(12):1470-1487.e7. PubMed ID: 36513049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
    Morgan MA; Schambach A
    Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma.
    Pawlowski KD; Duffy JT; Gottschalk S; Balyasnikova IV
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
    Bocca P; Di Carlo E; Caruana I; Emionite L; Cilli M; De Angelis B; Quintarelli C; Pezzolo A; Raffaghello L; Morandi F; Locatelli F; Pistoia V; Prigione I
    Oncoimmunology; 2017; 7(1):e1378843. PubMed ID: 29296542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
    Quintarelli C; Orlando D; Boffa I; Guercio M; Polito VA; Petretto A; Lavarello C; Sinibaldi M; Weber G; Del Bufalo F; Giorda E; Scarsella M; Petrini S; Pagliara D; Locatelli F; De Angelis B; Caruana I
    Oncoimmunology; 2018; 7(6):e1433518. PubMed ID: 29872565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.